Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Immuneering Corp issued $25.0 million of shares of the Company's Class A common stock or, in certain circumstances, shares of the Company's non-voting Class B common stock of common stock to Aventis Inc. for The price per Share will be the price per share of Class A Common Stock to the public in the Public Offering as set forth on the cover of the definitive prospec.
- Security
- common stock
- Shares
- $25.0 million of shares of the Company's Class A common stock or, in certain circumstances, shares of the Company's non-voting Class B common stock
- Purchaser
- Aventis Inc.
- Consideration
- The price per Share will be the price per share of Class A Common Stock to the public in the Public Offering as set forth on the cover of the definitive prospec
Exact text from the filing
On September 24, 2025, Immuneering Corporation (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with Aventis Inc. (the "Investor"), a wholly owned subsidiary of Sanofi, a French société anonyme, pursuant to which the Company, in a private placement transaction (the "Private Placement"), agreed to issue and sell to the Investor $25.0 million of shares (the "Class A Shares") of the Company's Class A common stock, par value $0.001 per share ("Class A Common Stock"), or in certain circumstances in lieu of Class A Shares, shares (the "Class B Shares" and, together with the Class A Shares, collectively, the "Shares") of the Company's non-voting Class B common stock, par value $0.001 per share ("Class B Common Stock"), subject to and contingent upon the closing of a firm commitment underwritten public offering of Class A Common Stock by the Company that results in gross proceeds to the Company of at least $75.0 million and the pricing of which is publicl
View on SEC.gov